Project Grant R01AI201728
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $727K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $445,000 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel immunoregulatory mechanisms that modulate myeloid trained immunity following transplantation. The research examines innate immune responses in transplant recipients, focusing on how monocytes expressing neuropilin 2 (NRP2) can...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $267,000 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory B cell function in transplant alloimmunity. The project examines whether neuropilin-2 (NRP2)-expressing B cell subsets promote immunoregulation and suppress CD4+ T effector cell activation in the context of organ transplant...
- The National Institute of Allergy and Infectious Diseases awarded Brigham and Women's Hospital Inc. $823,143 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate regulatory T cell (Treg) defects in amyotrophic lateral sclerosis. The research aims to identify why Tregs are functionally deficient in ALS patients and what causes their reduced frequency. Prior evidence shows that ALS patients exhibit lower Treg frequency and reduced Treg function...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,074,434.37 Project Grant to the Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 17, 2021 with a completion date of July 12, 2021. The grant funding supports research to develop protocols to induce tolerance in non-human primate heart allograft recipients without chronic immunosuppression. The awardee will test approaches to either...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $893,459 on April 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R01AI189471. The award funds lipidomic discovery of lipid antigens presented by CD1 molecules to human T cells and the development of lipid-based inhibitors that block T cell activation. The research uses a sensitive lipidomics platform to comprehensively detect hundreds of...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded Beckman Research Institute of the City of Hope $888,941 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical research on regulatory T cell-mediated thymic regeneration after hematopoietic cell transplantation. The research addresses thymic injury caused by allogeneic hematopoietic cell transplantation preconditioning, which increases risk of malignancies,...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $388,800 on September 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will characterize vaccine immunogenicity and adoptive transfer of humoral and cellular immunity in allogeneic hematopoietic stem cell transplant (HCT) recipients in response to mRNA SARS-CoV-2 vaccination. The project will analyze the relationship between donor and recipient...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $100,228 on November 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). MIT will conduct research examining the molecular basis of T cell allorecognition in graft-versus-host disease and graft-versus-leukemia. The research uses a repertoire-scale examination to determine the molecular mechanisms underlying T cell recognition of non-self major...